Muireann Bolger

Key details

Muireann Bolger is deputy editor of World Intellectual Property Review and Life Sciences Intellectual Property Review in London, where she covers trademarks, brands, as well as wider developments across the intellectual property sector.

She regularly attends and covers major IP conferences around the world, reporting on the latest legal, commercial and policy developments and interviewing leading figures from across the sector. She has also co-authored industry reports with leading IP organisations, including the International Trademark Association (INTA).

She is the editor of the website’s Community & Inclusion channel and the annual Influential Women in IP list, which celebrates the achievements and contributions of leading women across the IP sector.

Originally from Ireland, Muireann has nearly two decades of experience reporting on brand developments, strategy, and wider business issues.

In her current role, she writes and edits news and analysis for an international audience of IP professionals, while also championing inclusion within the profession.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 415

Articles by Muireann Bolger

Withers & Rogers hires cell and gene therapy expert
Careers
Skilled in microbiome, medical devices and next generation diagnostics, the new partner is skilled in creating IP strategies for startups, spinouts and SMEs.   9 January 2025
Tissue repair VP gets new trial over secrets damages
Americas
Case concerns allegations that ex-senior vice president of business development at Skye Orthobiologics misappropriated secrets and breached contract | Companies in dispute process and manufacture medical products derived from human placental tissue.   7 January 2025
 Fed Circ orders Teva to delist five patents from Orange Book
Americas
Dispute stems from Amneal’s efforts to market generic version of Teva’s inhaler for treating asthma | Precedential decision could restrict how brand-name pharmaceutical companies use the Orange Book to extend market exclusivity.   24 December 2024
Americas
Pair of generic drug makers challenged validity of patent on priority, novelty and inventive step | EPO found the patent did not introduce any new matter not originally disclosed in the pharma company’s application.   19 December 2024
Americas
Regeneron inks deal over suit concerning a protein for testing COVID-19 treatments | BioNTech aims to resolve university dispute over patented tech used in the Comirnaty vaccine.   17 December 2024
Americas
Corporate legal teams can embrace the AI revolution by encouraging experimentation and managing risks proactively, according to a recent panel featuring leading pharma counsel.   10 December 2024
Asia
Agreement provides for €140 million in upfront and additional payments to Cytokinetics and up to €490 million in milestone payments, with tiered royalties on future sales | “Important regional deal” comes as Bayer’s new partner eyes US and European markets.   21 November 2024
Careers
Former patent examiner and federal clerk brings expertise in cutting-edge technologies to the US firm.   17 October 2024
Americas
Danish pharma company asserts 10 patents for drug that improves blood sugar levels in Type 2 diabetes patients | Like Novo’s Ozempic, the disputed drug can be used off-label to achieve weight loss.   15 October 2024
Europe
Value-for-money UPC is worth it says GSK corporate counsel | Court offers alternative to costly US litigation | Head of vaccine patents says UPC offers “strategic plank” in Europe.   10 October 2024

Not finding what you're looking for, please try resetting your applied search and filters,
or try the
full site search.